Mark M Pomerantz1, Sandor Spisák1, Li Jia2, Angel M Cronin3, Istvan Csabai4, Elisa Ledet5, A Oliver Sartor5, Irene Rainville3, Edward P O'Connor1, Zachary T Herbert1, Zoltan Szállási6, William K Oh7, Philip W Kantoff8, Judy E Garber3, Deborah Schrag3, Adam S Kibel2, Matthew L Freedman1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Surgery, Division of Urology, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Physics of Complex Systems Eotvos Lorand University, Budapest, Hungary. 5. Department of Medicine, Tulane Cancer Center, New Orleans, Louisiana. 6. Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts. 7. Department of Medicine, Division of Hematology and Oncology, Tisch Cancer Institute, New York, New York. 8. Department of Medicine, Memorial Sloan Kettering Cancer Institute, New York, New York.
Abstract
BACKGROUND: Breast cancer 2 (BRCA2)-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy. It is unknown whether BRCA2-associated prostate cancer responds favorably to such treatment. METHODS: A retrospective analysis of a single-institution cohort of men with castration-resistant, metastatic prostate cancer was performed to determine the association between carrier status of pathogenic BRCA2 germline variants and prostate-specific antigen response to carboplatin-based chemotherapy. From 2001 through 2015, 8081 adult men with prostate cancer who had a consultation and/or underwent treatment at Dana-Farber Cancer Institute provided blood samples and consented to analyses of biologic material and clinical records. A subgroup of 141 men received at least 2 doses of carboplatin and docetaxel for castration-resistant disease (94% were also taxane refractory). These patients were categorized according to the absence or presence of pathogenic germline mutations in BRCA2 based on DNA sequencing from whole blood. The primary outcome was the response rate to carboplatin/docetaxel chemotherapy, defined according to a decline in prostate-specific antigen that exceeded 50% within 12 weeks of initiating this regimen. Associations between BRCA2 mutation status and response to carboplatin-based chemotherapy were tested using the Fisher exact test, with a 2-sided P value < .05 as the threshold for significance. RESULTS: Pathogenic germline BRCA2 variants were observed in 8 of 141 men (5.7%; 95% confidence interval, 2.5%-10.9%). Six of 8 BRCA2 carriers (75%) experienced prostate-specific antigen declines >50% within 12 weeks, compared with 23 of 133 noncarriers (17%; absolute difference, 58%; 95% confidence interval, 27%-88%; P < .001). Prostate cancer cell lines functionally corroborated these clinical findings. CONCLUSIONS: BRCA2-associated, castration-resistant prostate cancer is associated with a higher likelihood of response to carboplatin-based chemotherapy than non-BRCA2-associated prostate cancer. Cancer 2017;123:3532-9.
BACKGROUND:Breast cancer 2 (BRCA2)-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy. It is unknown whether BRCA2-associated prostate cancer responds favorably to such treatment. METHODS: A retrospective analysis of a single-institution cohort of men with castration-resistant, metastatic prostate cancer was performed to determine the association between carrier status of pathogenic BRCA2 germline variants and prostate-specific antigen response to carboplatin-based chemotherapy. From 2001 through 2015, 8081 adult men with prostate cancer who had a consultation and/or underwent treatment at Dana-Farber Cancer Institute provided blood samples and consented to analyses of biologic material and clinical records. A subgroup of 141 men received at least 2 doses of carboplatin and docetaxel for castration-resistant disease (94% were also taxane refractory). These patients were categorized according to the absence or presence of pathogenic germline mutations in BRCA2 based on DNA sequencing from whole blood. The primary outcome was the response rate to carboplatin/docetaxel chemotherapy, defined according to a decline in prostate-specific antigen that exceeded 50% within 12 weeks of initiating this regimen. Associations between BRCA2 mutation status and response to carboplatin-based chemotherapy were tested using the Fisher exact test, with a 2-sided P value < .05 as the threshold for significance. RESULTS: Pathogenic germline BRCA2 variants were observed in 8 of 141 men (5.7%; 95% confidence interval, 2.5%-10.9%). Six of 8 BRCA2 carriers (75%) experienced prostate-specific antigen declines >50% within 12 weeks, compared with 23 of 133 noncarriers (17%; absolute difference, 58%; 95% confidence interval, 27%-88%; P < .001). Prostate cancer cell lines functionally corroborated these clinical findings. CONCLUSIONS:BRCA2-associated, castration-resistant prostate cancer is associated with a higher likelihood of response to carboplatin-based chemotherapy than non-BRCA2-associated prostate cancer. Cancer 2017;123:3532-9.
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: J Chen; D P Silver; D Walpita; S B Cantor; A F Gazdar; G Tomlinson; F J Couch; B L Weber; T Ashley; D M Livingston; R Scully Journal: Mol Cell Date: 1998-09 Impact factor: 17.970
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles Journal: Br J Cancer Date: 2011-09-27 Impact factor: 7.640
Authors: Elizabeth K Bancroft; Elizabeth C Page; Elena Castro; Hans Lilja; Andrew Vickers; Daniel Sjoberg; Melissa Assel; Christopher S Foster; Gillian Mitchell; Kate Drew; Lovise Mæhle; Karol Axcrona; D Gareth Evans; Barbara Bulman; Diana Eccles; Donna McBride; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Cezary Cybulski; Dominika Wokolorczyk; Christina Selkirk; Peter J Hulick; Anders Bojesen; Anne-Bine Skytte; Jimmy Lam; Louise Taylor; Rogier Oldenburg; Ruben Cremers; Gerald Verhaegh; Wendy A van Zelst-Stams; Jan C Oosterwijk; Ignacio Blanco; Monica Salinas; Jackie Cook; Derek J Rosario; Saundra Buys; Tom Conner; Margreet G Ausems; Kai-ren Ong; Jonathan Hoffman; Susan Domchek; Jacquelyn Powers; Manuel R Teixeira; Sofia Maia; William D Foulkes; Nassim Taherian; Marielle Ruijs; Apollonia T Helderman-van den Enden; Louise Izatt; Rosemarie Davidson; Muriel A Adank; Lisa Walker; Rita Schmutzler; Kathy Tucker; Judy Kirk; Shirley Hodgson; Marion Harris; Fiona Douglas; Geoffrey J Lindeman; Janez Zgajnar; Marc Tischkowitz; Virginia E Clowes; Rachel Susman; Teresa Ramón y Cajal; Nicholas Patcher; Neus Gadea; Allan Spigelman; Theo van Os; Annelie Liljegren; Lucy Side; Carole Brewer; Angela F Brady; Alan Donaldson; Vigdis Stefansdottir; Eitan Friedman; Rakefet Chen-Shtoyerman; David J Amor; Lucia Copakova; Julian Barwell; Veda N Giri; Vedang Murthy; Nicola Nicolai; Soo-Hwang Teo; Lynn Greenhalgh; Sara Strom; Alex Henderson; John McGrath; David Gallagher; Neil Aaronson; Audrey Ardern-Jones; Chris Bangma; David Dearnaley; Philandra Costello; Jorunn Eyfjord; Jeanette Rothwell; Alison Falconer; Henrik Gronberg; Freddie C Hamdy; Oskar Johannsson; Vincent Khoo; Zsofia Kote-Jarai; Jan Lubinski; Ulrika Axcrona; Jane Melia; Joanne McKinley; Anita V Mitra; Clare Moynihan; Gad Rennert; Mohnish Suri; Penny Wilson; Emma Killick; Sue Moss; Rosalind A Eeles Journal: Eur Urol Date: 2014-01-15 Impact factor: 20.096
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Chao Liang; Hao Wang; Yan Chen; John L Silberstein; Danilo Piana; Zhao Lai; Yidong Chen; William B Isaacs; Jun Luo Journal: Eur Urol Date: 2018-02-10 Impact factor: 20.096
Authors: Emmanuel S Antonarakis; Pedro Isaacsson Velho; Wei Fu; Hao Wang; Neeraj Agarwal; Victor Sacristan Santos; Benjamin L Maughan; Roberto Pili; Nabil Adra; Cora N Sternberg; Panagiotis J Vlachostergios; Scott T Tagawa; Alan H Bryce; Andrea L McNatty; Zachery R Reichert; Robert Dreicer; Oliver Sartor; Tamara L Lotan; Maha Hussain Journal: JCO Precis Oncol Date: 2020-04-21
Authors: Srinivas R Viswanathan; Gavin Ha; Andreas M Hoff; Jeremiah A Wala; Jian Carrot-Zhang; Christopher W Whelan; Nicholas J Haradhvala; Samuel S Freeman; Sarah C Reed; Justin Rhoades; Paz Polak; Michelle Cipicchio; Stephanie A Wankowicz; Alicia Wong; Tushar Kamath; Zhenwei Zhang; Gregory J Gydush; Denisse Rotem; J Christopher Love; Gad Getz; Stacey Gabriel; Cheng-Zhong Zhang; Scott M Dehm; Peter S Nelson; Eliezer M Van Allen; Atish D Choudhury; Viktor A Adalsteinsson; Rameen Beroukhim; Mary-Ellen Taplin; Matthew Meyerson Journal: Cell Date: 2018-06-18 Impact factor: 41.582
Authors: Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli Journal: JCO Precis Oncol Date: 2019-09-17
Authors: Jose Mauricio Mota; Ethan Barnett; Jones T Nauseef; Bastien Nguyen; Konrad H Stopsack; Andreas Wibmer; Jessica R Flynn; Glenn Heller; Daniel C Danila; Dana Rathkopf; Susan Slovin; Philip W Kantoff; Howard I Scher; Michael J Morris; Nikolaus Schultz; David B Solit; Wassim Abida Journal: JCO Precis Oncol Date: 2020-04-16